Taiwan firms aim to expand hep B treatment with generic Baraclude
This article was originally published in Scrip
Executive Summary
Two Taiwanese firms are planning to launch a generic version of Bristol-Myers Squibb's hepatitis B drug Baraclude (entecavir) in their home market by the end of the year, in a move they expect to improve low treatment rates for the disease.